ACQUISITIONS (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Oct. 31, 2016 |
Sep. 30, 2016 |
Dec. 31, 2017 |
Sep. 13, 2017 |
Dec. 31, 2016 |
Apr. 02, 2016 |
|
| Consideration for assets acquired | $ 6,839,925 | |||||
| Common stock, shares issued | 9,500,206 | |||||
| Replacement cost of finished goods | $ 3,293,150 | $ 853,066 | ||||
| Purchase price of assets acquired | 1,250,000 | |||||
| Closing price of common stock | $ 3.30 | |||||
| Trademarks [Member] | ||||||
| Purchase price of assets acquired | $ 300,000 | |||||
| Trademarks [Member] | Minimum [Member] | ||||||
| Finite lived intangible asset, useful life | 2 years | |||||
| Trademarks [Member] | Maximum [Member] | ||||||
| Finite lived intangible asset, useful life | 8 years | |||||
| Convertible Series Q Preferred Stock [Member] | ||||||
| Debt conversion, converted instrument, shares issued | 7,126,000 | |||||
| Series Z Preferred Stock [Member] | ||||||
| Debt conversion, converted instrument, shares issued | 1,010,951 | |||||
| Asset purchase agreement [Member] | ||||||
| Cash paid as consideration | $ 4,120,791 | |||||
| Common stock, shares issued | 633,348 | |||||
| Common stock shares issued, value | $ 2,090,046 | |||||
| Black Oak acquisition [Member] | ||||||
| Purchase price of assets acquired | $ 51,489,665 | |||||
| Closing price of common stock | $ 3.93 | |||||
| Black Oak acquisition [Member] | Purchase price one [Member] | ||||||
| Business acquisition purchase price, description |
the issuance of approximately 78 shares of our Series Z Preferred Stock (or, upon conversion, 783,949 shares of our common stock), approximately 83,220 shares of our Series B Preferred Stock (or, upon conversion, 448,084 shares of our common stock), and approximately 246 shares of our Series Q Preferred Stock (or, upon conversion, 1,232,033 shares of our common stock), which collectively, were converted into 2,464,066 shares of our common stock (the Closing Consideration) |
|||||
| Black Oak acquisition [Member] | Purchase price two [Member] | ||||||
| Business acquisition purchase price, description |
the issuance of approximately 281 shares of our Series Z Preferred Stock (or, upon conversion, 2,806,553 shares of our common stock), approximately 297,925 shares of our Series B Preferred Stock (or, upon conversion, 1,604,124 shares of our common stock), and approximately 596 shares of our Series Q Preferred Stock (or, upon conversion, 2,981,520 shares of our common stock), which collectively, were converted into approximately 7,392,197 shares of our common stock (the Lockup Consideration) |
|||||
| Black Oak acquisition [Member] | Purchase price three [Member] | ||||||
| Business acquisition purchase price, description |
the issuance of approximately 185 shares of our Series Z Preferred Stock (or, upon conversion, 1,853,607 shares of our common stock), approximately 196,769 shares of our Series B Preferred Stock (or, upon conversion, 1,059,466 shares of our common stock), and approximately 583 shares of our Series Q Preferred Stock (or, upon conversion, 2,913,073 shares of our common stock), which collectively, were converted into approximately 5,826,147 shares of our common stock (the Holdback Consideration) |
|||||
| Black Oak acquisition [Member] | Purchase price four [Member] | ||||||
| Business acquisition purchase price, description |
the contingent cash consideration of up to $2,088,000 pursuant to certain earn-out provisions set forth in the Merger Agreement, payable to the Group B Shareholders (the Performance-Based Cash Consideration). |
|||||
| Therapeutics Medical [Member] | ||||||
| Consideration for assets acquired | $ 1,250,000 | |||||
| Replacement cost of finished goods | 58,622 | |||||
| Issuance of convertible promissory note as purchase consideration | $ 1,250,000 | |||||
| Convertible promissory note maturity date | Sep. 10, 2017 | |||||
| Debt conversion description |
Companys common stock at a conversion price equal to 90% of the average of the lowest three volume-weighted average prices of one share of common stock for the five consecutive trading days prior to the conversion date. |
|||||
| Debt conversion, converted instrument, shares issued | 189,193 | |||||
| Weighted-average price per share | $ 6.60 | |||||
| Therapeutics Medical [Member] | Trademarks [Member] | ||||||
| Acquired of intangible assets | $ 300,000 | |||||
| Therapeutics Medical [Member] | Trademarks [Member] | Minimum [Member] | ||||||
| Finite lived intangible asset, useful life | 8 years | |||||
| Therapeutics Medical [Member] | Trademarks [Member] | Maximum [Member] | ||||||
| Finite lived intangible asset, useful life | 12 years | |||||
| Therapeutics Medical [Member] | Customer Relationship [Member] | ||||||
| Finite lived intangible asset, useful life | 5 years | |||||
| Therapeutics Medical [Member] | Customer list [Member] | ||||||
| Acquired of intangible assets | $ 888,300 | |||||
| Therapeutics Medical [Member] | Patents [Member] | ||||||
| Acquired of intangible assets | $ 3,078 | |||||
| Escrow [Member] | ||||||
| Common stock, shares issued | 192,758 | |||||
| Common stock shares issued, value | $ 636,100 | |||||
| Tech Center Drive [Member] | ||||||
| Due from related parties | $ 316,363 | |||||